Mounjaro® and Zepbound® contain the exact same active ingredient — tirzepatide, made by Eli Lilly — but they're FDA-approved for different reasons. Mounjaro® is approved for type 2 diabetes; Zepbound® is approved for chronic weight management. Unlike Novo Nordisk's semaglutide brands, the two share the same dose range and titration schedule. The approval, the marketing, and the insurance outcome are what differ — not the dose ceiling.
Quick comparison
| Mounjaro® | Zepbound® | |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly |
| FDA-approved for | Type 2 diabetes (glycemic control) | Chronic weight management |
| First approved | 2022 | 2023 |
| Dose range | 2.5–15 mg weekly | 2.5–15 mg weekly |
| Titration | 6 steps, ~5 months to max dose | 6 steps, ~5 months to max dose |
| Brand-name cost (no insurance) | ~$1,100/mo | ~$1,130/mo |
| Self-pay program | — | LillyDirect vials (~$349–$499/mo) |
| Typically covered by insurance for | Type 2 diabetes diagnosis | Rarely — weight-loss coverage is inconsistent |
Both are cash-pay through Pallas; not billed to insurance.
Same drug, different approval
Tirzepatide is a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist — it mimics two natural gut hormones instead of one, which is part of why it produces such strong effects on both blood sugar and appetite. Eli Lilly developed and markets it under two brand names because each was studied and approved for a different purpose:
- Mounjaro® was FDA-approved in 2022 to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. Its pivotal trials (the SURPASS program) measured glycemic control — HbA1c reduction — as the primary endpoint; weight change was tracked as a secondary outcome, not the basis for approval.
- Zepbound® was FDA-approved in 2023 for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. Its pivotal trial, SURMOUNT-1, was designed around weight loss as the primary endpoint — participants lost an average of 20.9% of body weight at 15 mg over 72 weeks.
The one-sentence version
Mounjaro® and Zepbound® are the same molecule at the same doses, approved by the FDA for different reasons — which is why a Mounjaro® prescription isn't a stand-in for Zepbound®, even though the drug inside the pen is identical.
For a deeper look at how the dual-receptor mechanism works, read our explainer on how GLP-1 and GIP work.
Dosing: the same schedule, for different reasons
This is where Mounjaro®/Zepbound® differs from Novo Nordisk's semaglutide brands. Ozempic® and Wegovy® top out at different maximum doses (2.0 mg vs 2.4 mg). Mounjaro® and Zepbound® don't — both follow the same six-step titration to the same maximum dose:
- Weeks 1–4: 2.5 mg
- Weeks 5–8: 5 mg
- Weeks 9–12: 7.5 mg
- Weeks 13–16: 10 mg
- Weeks 17–20: 12.5 mg
- Week 21+: 15 mg (maximum)
Your prescribing clinician sets your pace and decides whether to advance to the next step based on how you tolerate each dose — the schedule above is a ceiling, not a target everyone reaches. Many patients on either product stay at a lower maintenance dose long-term.
Can Mounjaro be used for weight loss?
Some clinicians do prescribe Mounjaro® off-label for weight loss, since it's the same active ingredient as Zepbound®. This happens in practice, but it comes with a real trade-off: because Mounjaro® is approved and labeled for diabetes, many insurance plans now require a documented type 2 diabetes diagnosis to cover it — coverage isn't automatic just because a prescription exists, and misrepresenting a diagnosis to obtain coverage is insurance fraud with real legal exposure, not a workaround.
If chronic weight management is your actual goal, Zepbound® is the product FDA-approved and studied specifically for that. Which product — and which dose — is appropriate for you is a clinical decision a licensed provider makes based on your diagnosis, history, and goals.
Side effects: nearly identical
Because they share the same active ingredient and mechanism, the side-effect profile is essentially the same for both, with intensity often tracking dose:
Most common:
- Nausea (typically most noticeable in the first 1–4 weeks after starting or after a dose increase)
- Diarrhea
- Constipation
- Vomiting
- Abdominal discomfort
Less common:
- Fatigue, especially early on
- Injection-site reactions
- Gallbladder issues (risk rises with more rapid weight loss)
Rare but serious: pancreatitis, severe allergic reactions, and a boxed warning for both products regarding a potential risk of thyroid C-cell tumors observed in animal studies — both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Most GI side effects ease within 4–8 weeks of starting or after each dose increase. For a full breakdown, see our complete guide to GLP-1 side effects.
Cost and insurance
Cash prices are close but not identical, even though the underlying drug is the same:
| Medication | Monthly cash price | Typical insurance path |
|---|---|---|
| Mounjaro® (tirzepatide, diabetes) | ~$1,100 | Often covered with a documented type 2 diabetes diagnosis |
| Zepbound® (tirzepatide, weight management) | ~$1,130 | Coverage for weight loss is inconsistent across commercial plans |
Eli Lilly's LillyDirect self-pay program offers Zepbound® single-dose vials at lower doses for roughly $349–$499/month. Medicare Part D can cover Mounjaro® for a documented type 2 diabetes diagnosis (typically a $35–$200/month copay), but Medicare is prohibited by law from covering medications prescribed for weight loss — so Zepbound® isn't a Medicare option regardless of diagnosis history.
For the fuller picture, including compounded tirzepatide as a separate, lower-cost cash-pay option, see our complete tirzepatide cost breakdown.
Which one is right for you?
This isn't really an either/or choice — it comes down to why you need tirzepatide in the first place:
- You have type 2 diabetes and need glycemic control (with or without a secondary weight-loss benefit): Mounjaro® is the product studied and approved for that.
- Your primary goal is chronic weight management, with or without diabetes: Zepbound® is the product studied and approved specifically for that.
- You have both type 2 diabetes and a weight-management goal: your clinician will factor in your diagnosis, insurance situation, and treatment history to recommend the more appropriate product for you.
A US-licensed clinician makes this call based on your history — not a fixed rule — and availability can vary by state. Check current options in the GLP-1 state directory, or read more about GLP-1 treatment at Pallas.
Bottom line: Mounjaro® and Zepbound® are the same active ingredient, tirzepatide, made by the same manufacturer, at the same doses — but they're approved for different reasons and priced and covered differently as a result. Mounjaro® is for type 2 diabetes; Zepbound® is for chronic weight management. A licensed clinician determines which product fits your diagnosis and goals.
